Effects of glucagon on insulin and cognitive function in healthy individuals
Investigating the Effect of Glucagon on Cognitive Function and Cerebral Glucose Metabolism in Humans: A Pilot Study
NA · University of Copenhagen · NCT06685146
This study tests how a hormone called glucagon affects insulin levels and thinking skills in healthy people compared to how glucose does.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 25 Years to 70 Years |
| Sex | All |
| Sponsor | University of Copenhagen (other) |
| Locations | 1 site (Copenhagen) |
| Trial ID | NCT06685146 on ClinicalTrials.gov |
What this trial studies
This study investigates how exogenous glucagon affects insulin secretion and cognitive function independently of glucose levels in healthy subjects. Participants will undergo two study days, one with a glucagon infusion and another with a glucose clamp to match glucose levels from the first day. Blood samples will be collected frequently to measure plasma glucagon, insulin, and C-peptide, while cognitive testing will be performed after the infusions. The goal is to compare the effects of glucagon and glucose on insulin secretion and cognitive performance.
Who should consider this trial
Good fit: Ideal candidates are healthy adults aged 25 to 70 with a BMI of 25 or lower.
Not a fit: Patients with diabetes, psychiatric disorders, or significant liver or kidney disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of glucagon's role in insulin regulation and cognitive function, potentially leading to new therapeutic strategies for metabolic disorders.
How similar studies have performed: While the specific glucose-independent effects of glucagon are less explored, similar studies on glucagon's role in metabolism have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Capable of understanding the participant information and signing the consent form * Between 25 and 70 years of age at the time of screening * Body mass index (BMI) ≤ 25 kg/m2 at the time of screening * A minimum of 7 years of schooling Exclusion Criteria: * Enrolment in other research projects that might interfere with the study * Diabetes diagnosis (type 1 and 2) * Pregnancy or breastfeeding * Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol * Diagnosis of psychiatric disorders, dementias, or any other neurological disorders that in the opinion of the investigator precludes compliance with the study protocol, evaluation of the results or represents an unacceptable risk for the participants safety * Severe claustrophobia * Impaired liver function defined as either alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) ≥ 2 times normal values * Kidney disease defined as serum creatinine levels ≥ 126 μmol/L for male and ≥ 111 μmol/L for female * Cardiac problems including any of the following: 1. Classified as being in New York Heart Association (NYHA) class III or IV 2. Angina pectoris (chest pain) within the last 6 months 3. Acute myocardial infarction (heart attack) within last 2 years * Inadequately treated blood pressure at screening defined as repeated resting blood pressure outside the range 90-150 mmHg for systolic and 50-100 mmHg for diastolic * Active or recent malignant disease * Inability to perform neuropsychological tests judged by the investigator (e.g. visual or auditory impairment or language barriers) * Current or history of severe alcohol use or drug/chemical abuse as per investigator's judgement * Any chronic disorders or severe diseases which, in the opinion of the investigator, might jeopardise participant's safety or compliance with the protocol
Where this trial is running
Copenhagen
- Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark — Copenhagen, Denmark (RECRUITING)
Study contacts
- Principal investigator: Nicolai J Wewer Albrecthsen, MD PhD — Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
- Study coordinator: Nina L Hansen, MD
- Email: nina.lerberg.hansen.01@regionh.dk
- Phone: 0045 21205944
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Glucose Metabolism, Insulin Secretion, Glucagon, Cognition, Glucose clamp, Insulin secretion, C-peptide